Monday, November 12, 2012

FDA Approves Xeljanz® for Rheumatoid Arthritis

Pfizer announced the U.S. Food and Drug Administration (FDA) approved Xeljanz® (tofacitinib nitrate) to treat adults with rheumatoid arthritis (RA) who can't take or have had poor response to methotrexate.

Xeljanz is a pill taken twice daily and works by blocking molecules called Janus kinases (JAK), which are specifically designed to inhibit the JAK pathways that play an important role in the joint inflammation of RA.

Congratulations to the volunteers, PMG Sites and Investigators who contributed to the development of a new rheumatoid arthritis medication through their participation in this clinical research study!
Please click here to learn more about Xeljanz.

No comments :

Post a Comment

Subscribe Via Email